ResMed Inc.

NYSE:RMD Stock Report

Market Cap: US$35.2b

ResMed Future Growth

Future criteria checks 2/6

ResMed is forecast to grow earnings and revenue by 9.8% and 7.2% per annum respectively. EPS is expected to grow by 9.2% per annum. Return on equity is forecast to be 21.6% in 3 years.

Key information

9.8%

Earnings growth rate

9.2%

EPS growth rate

Medical Equipment earnings growth12.7%
Revenue growth rate7.2%
Future return on equity21.6%
Analyst coverage

Good

Last updated02 May 2025

Recent future growth updates

Recent updates

ResMed: Cornering The Market In Sleep Solutions

Apr 24

ResMed Inc. (NYSE:RMD) Shares Could Be 32% Below Their Intrinsic Value Estimate

Apr 15
ResMed Inc. (NYSE:RMD) Shares Could Be 32% Below Their Intrinsic Value Estimate

If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity

Feb 26
If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity

ResMed Inc.'s (NYSE:RMD) Share Price Not Quite Adding Up

Feb 14
ResMed Inc.'s (NYSE:RMD) Share Price Not Quite Adding Up

Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions

Feb 10

ResMed: Snoozers Can Be Winners

Feb 01

ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)

Jan 24

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price

Jan 13
ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price

ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency

Jan 01
ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency

ResMed: Solid Execution, Pricey Valuation

Nov 25

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Oct 20
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Oct 08
ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Why ResMed's Rally Is Just Getting Started

Sep 18

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

Sep 13
ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

Earnings and Revenue Growth Forecasts

NYSE:RMD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20275,9541,6691,6331,75321
6/30/20265,5401,5031,4991,60026
6/30/20255,1241,3611,3851,46124
3/31/20255,0221,3131,5601,653N/A
12/31/20244,9271,2491,3841,476N/A
9/30/20244,8071,1131,3471,441N/A
6/30/20244,6851,0211,2861,401N/A
3/31/20244,5849581,0711,199N/A
12/31/20234,5048909441,079N/A
9/30/20234,375907792935N/A
6/30/20234,223898559693N/A
3/31/20234,016863408535N/A
12/31/20223,763809222370N/A
9/30/20223,624786305461N/A
6/30/20223,578779195351N/A
3/31/20223,539779344498N/A
12/31/20213,444522446577N/A
9/30/20213,349500397527N/A
6/30/20213,197475620737N/A
3/31/20213,091457733840N/A
12/31/20203,092699774884N/A
9/30/20203,028680684784N/A
6/30/20202,957622696802N/A
3/31/20202,892513505614N/A
12/31/20192,784455420514N/A
9/30/20192,699419487573N/A
6/30/20192,607405382459N/A
3/31/20192,525446374447N/A
12/31/20182,455450N/A456N/A
9/30/20182,405335N/A459N/A
6/30/20182,340316N/A505N/A
3/31/20182,273307N/A516N/A
12/31/20172,196285N/A434N/A
9/30/20172,125352N/A422N/A
6/30/20172,067342N/A414N/A
3/31/20172,029324N/A417N/A
12/31/20161,968327N/A474N/A
9/30/20161,893346N/A510N/A
6/30/20161,839352N/A548N/A
3/31/20161,773357N/A505N/A
12/31/20151,742357N/A471N/A
9/30/20151,710353N/A421N/A
6/30/20151,679353N/A383N/A
3/31/20151,641353N/A399N/A
12/31/20141,616352N/A409N/A
9/30/20141,578348N/A387N/A
6/30/20141,555345N/A391N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RMD's forecast earnings growth (9.8% per year) is above the savings rate (2.8%).

Earnings vs Market: RMD's earnings (9.8% per year) are forecast to grow slower than the US market (13.9% per year).

High Growth Earnings: RMD's earnings are forecast to grow, but not significantly.

Revenue vs Market: RMD's revenue (7.2% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: RMD's revenue (7.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RMD's Return on Equity is forecast to be high in 3 years time (21.6%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 00:04
End of Day Share Price 2025/05/05 00:00
Earnings2025/03/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ResMed Inc. is covered by 59 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterANZ Equities Pty Limited
Michael PolarkBaird
David RescottBaird